[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369684-105":3,"doc-detail-369684-en":81,"detail-sidebar-cat-0-en-105":115},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","usp25-maintains-kras-expression-and-inhibiting-the-deubiquitinase-suppresses-kras-signaling-in-human-cancer","USP25 maintains KRAS expression and inhibiting the deubiquitinase suppresses KRAS signaling in human cancer","","USP25 regulates KRAS stability in human cancer by controlling ubiquitin-mediated proteasomal degradation. In cancer cells, KRAS and activating mutants undergo ubiquitin-dependent turnover, and an siRNA-based deubiquitinase screen identifies USP25 as the responsible DUB. Reducing USP25 increases KRAS ubiquitination and proteasomal degradation, suppressing oncogenic signaling, downstream MAP kinase pathway activity, and cell proliferation. Pharmacologic USP25 inhibitors destabilize KRAS and inhibit tumor xenograft growth in mice, supporting USP25 as a therapeutic target for KRAS-driven tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/usp25-maintains-kras-expression-and-inhibiting-the-deubiquitinase-suppresses-kras-signaling-in-human-cancer/369684/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/usp25-maintains-kras-expression-and-inhibiting-the-deubiquitinase-suppresses-kras-signaling-in-human-cancer/369684.png","ImageObject",300,407,{"name":42,"@type":43},"Cipher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"USP25 plays what role in KRAS regulation in cancer cells?","Question",{"text":63,"@type":64},"USP25 functions as a deubiquitinase that maintains KRAS expression by preventing ubiquitin-mediated proteasomal degradation of KRAS.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does USP25 depletion affect KRAS ubiquitination and downstream signaling?",{"text":68,"@type":64},"Depleting USP25 increases KRAS ubiquitination and proteasomal degradation, which suppresses downstream MAP kinase pathway signaling and reduces cell proliferation.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports USP25 as a target for KRAS-driven tumors?",{"text":72,"@type":64},"USP25 inhibitors destabilize KRAS in cancer cells and are effective at blocking tumor xenograft growth in mice, indicating USP25 inhibition can indirectly suppress KRAS activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369684,1790215703,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":86,"file_id":87,"file_url":88,"file_type":89,"file_size":90,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":91,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97,"preview_page_count":33,"preview_urls":98},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","RESEARCH ARTICLE  \nUSP25 maintains KRAS expression and inhibiting the  \ndeubiquitinase suppresses KRAS signaling in human cancer  \nReceived for publication, December 4, 2024, and in revised form, May 21, 2025 Published, Papers in Press, June 3, 2025, [https://doi.org/10.1016/j.jbc.2025.1](https://doi.org/10.1016/j.jbc.2025.1)10337  \nHuailu Ma 1,2,3,‡, Huiyuan Guan 1,2,3,‡, Xiao Sun4,‡, Lingzhi Wu 1, Mengjiao Cai4, Xinghua Zhen 1, Xiang Shen5, Suxia Han4, Guangxue Liu 1,2,3, *, Jin Peng 1,2,3, *, and Pumin Zhang 1,2,3, *  \nFrom the 1Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Afﬁliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China; 2Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; 3Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China; 4Department of Oncology, The First Afﬁliated Hospital, Xi’an Jiaotong University Medical College, Xi’an, China; 5Chaser Therapeutics, Hangzhou, Zhejiang Province, China  \nReviewed by members of the JBC Editorial Board. Edited by Paul Shapiro  \nKRAS is a prominent oncogene mutated in a large number of human malignancies, particularly in pancreatic, colorectal, and lung tumors. We demonstrate here that KRAS, including its various activating mutants, is subjected to ubiquitin-mediated proteasomal degradation in cancer cells. Through an siRNAbased screening of deubiquitinases, we identiﬁed USP25 asa deubiquitinase for KRAS. Depleting USP25 expression increases ubiquitination and proteasomal degradation of KRAS, leading to the suppression of its oncogenic activity. We further show that USP25 inhibitors we have discovered are capable of destabilizing KRAS in cancer cells and are efﬁcacious in blocking tumor xenograft growth in mice. These ﬁndings provide evidence supporting the notion that targeting the deubiquitinase USP25 can effectively, albeit indirectly, suppress KRAS and potentially aid in the treatment of tumors driven by KRAS-activating mutations.  \nThe ubiquitin-proteasome system is critical in maintaining cellular protein homeostasis. Proteins destined for proteasomal degradation are usually labeled by polyubiquitin chains linked via the lysine 48 or the lysine 11 residues in ubiquitin (1, 2). This labeling process involves a series of enzymatic reactions mediated by three enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase), with E3s being responsible for determining substrate speciﬁcity (2–4). The poly-ubiquitin modiﬁcation can be removed to achieve protein homeostasis by deubiquitinases (DUBs), a class of specialized proteases that removes polyubiquitin chains from protein substrates (5–9).  \nRAS proteins have been shown to undergo ubiquitinmediated regulations. Three E3 ubiquitin ligases have been reported to facilitate RAS polyubiquitination and subsequent degradation, b-TRCP for HRAS (10); NEDD4-1 (11) and WDR76 (12) for all three RAS homologs. An additional E3 ligase, leucine-zipper–like transcriptional regulator 1 (LZTR1), was found responsible for monoubiquitination and  \n‡ These authors contributed equally to this work.  \n* For correspondence: Guangxue Liu, [1321294@zju.edu.cn](1321294@zju.edu.cn); Jin Peng, [pengjin0000@126.com](pengjin0000@126.com); Pumin Zhang, [pzhangbcm@zju.edu.cn](pzhangbcm@zju.edu.cn).  \ndiubiquitination of RAS proteins. This monoubiquitin/diubiquitin modiﬁcation interferes with the proper localization of RAS GTPases to the plasma membrane and disrupts RAS signaling (13, 14). Recent evidence also suggests that LZTR1 may polyubiquitinate RAS for degradation (15, 16), which is regulated by GSK and implicated in neoplastic transformation (16). Genetic studies in fruit ﬂy as well as in mice indicate that the preferred substrate of LZTR1 is actually RIT1, a noncanonical RAS protein (17). Both LZTR1 andRIT1 are mutated in Noonan syndrome, a condition characterized by RAS overactivation(18). These results reveal that ","cbCaiqO3S0eVhieG","https://ap.wps.com/l/cbCaiqO3S0eVhieG","pdf",4838138,14,"English","# Results\n## Identification of DUBs that control KRAS protein expression\n## USP25 is a DUB for KRAS","[{\"question\":\"USP25 plays what role in KRAS regulation in cancer cells?\",\"answer\":\"USP25 functions as a deubiquitinase that maintains KRAS expression by preventing ubiquitin-mediated proteasomal degradation of KRAS.\"},{\"question\":\"How does USP25 depletion affect KRAS ubiquitination and downstream signaling?\",\"answer\":\"Depleting USP25 increases KRAS ubiquitination and proteasomal degradation, which suppresses downstream MAP kinase pathway signaling and reduces cell proliferation.\"},{\"question\":\"What evidence supports USP25 as a target for KRAS-driven tumors?\",\"answer\":\"USP25 inhibitors destabilize KRAS in cancer cells and are effective at blocking tumor xenograft growth in mice, indicating USP25 inhibition can indirectly suppress KRAS activity.\"}]","USP25 maintains KRAS expression and inhibiting the deubiquitinase suppresses KRAS signaling in human cancer | PDF",1790184104,35,[99,103,107,111],{"page_no":22,"url":100,"width":101,"height":102},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10e4cf7bed95a2f6dfc35f34de1c8d70.webp",983,1296,{"page_no":26,"url":104,"width":105,"height":106},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ff92e7889d1edb5b2f47f792b92d758.webp",982,1294,{"page_no":30,"url":108,"width":109,"height":110},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f5f8629f6ef077d389bda4a471486ae.webp",981,1293,{"page_no":33,"url":112,"width":113,"height":114},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aac4f43051715b9a31ea6e62638efc69.webp",980,1292,{"code":4,"msg":82,"data":116},[117,121,125,129,134,139,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":118,"show_sort_weight":119,"slug":120},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":122,"show_sort_weight":123,"slug":124},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":126,"show_sort_weight":127,"slug":128},"Exam",70,"exam",{"id":130,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},5,"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":130,"slug":162},19,"General","general"]